| Drug Name |
Cyclobenzaprine |
| Drug ID |
BADD_D00545 |
| Description |
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977.[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. |
| Indications and Usage |
Cyclobenzaprine is indicated as a short-term (2-3 weeks) adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease, or spasticity in children with cerebral palsy.[L8408,L8411] Cyclobenzaprine is also occasionally used off-label for reducing pain and sleep disturbances in patients with fibromyalgia.[A184946] |
| Marketing Status |
approved |
| ATC Code |
M03BX08 |
| DrugBank ID |
DB00924
|
| KEGG ID |
D07758
|
| MeSH ID |
C004704
|
| PubChem ID |
2895
|
| TTD Drug ID |
D01KHH
|
| NDC Product Code |
53002-3080; 70518-0082; 70518-3159; 51655-973; 60687-558; 63187-812; 0615-8084; 51927-0118; 50268-191; 69097-846; 50436-0401; 61919-305; 53002-0521; 58118-0846; 69097-845 |
| UNII |
69O5WQQ5TI
|
| Synonyms |
cyclobenzaprine | Flexeril | Lisseril | cyclobenzaprine hydrochloride |
